Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer

Oncology Letters

Volumn 5, Issue 3, 2013, Pages 761-767

  Shimizu, Toshiki ^a   Yokoi, Takashi ^a   Tamaki, Takeshi ^a   Kibata, Kayoko ^a   Inagaki, Noriko ^a   Nomura, Shosaku ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Carboplatin; Neutropenia; Non small cell lung cancer; Paclitaxel; Weekly

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DRUG RESPONSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84872701151     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1134     Document Type: Article

References (23)

1. D'Addario G, Pintilie M, Leighl NB, et al: Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23: 2926-2936, 2005.
2. Ohe Y, Ohashi Y, Kubota K, et al: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323, 2007.
3. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.
4. Belani CP, Ramalingam S, Perry MC, et al: Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 26: 468-473, 2008.
5. Socinski MA, Ivanova A, Bakri K, et al: A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 17: 104-109, 2006.
6. Quoix E, Zalcman G, Oster JP, et al: Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 378: 1079-1088, 2011.
7. Hirabayashi M, Endoh K, Teramachi M, et al: Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study. Lung Cancer 44: 355-362, 2004.
8. Shitara K, Matsuo K, Oze I, et al: Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol 68: 301-307, 2010.
9. Kishida Y, Kawahara M, Teramukai S, et al: Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03. Br J Cancer 101: 1537-1542, 2009.
10. Di Maio M, Gridelli C, Gallo C, et al: Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6: 669-677, 2005.
11. Pallis AG, Agelaki S, Kakolyris S, et al: Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. Lung Cancer 62: 356-363, 2008.
12. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997.
13. Sobin L and Wittekind CH (eds): TNM Classification of Malignant Tumours. 6th edition. Wiley-Liss, New York, NY, pp99-103, 2002.
14. National Cancer Institute (NCI): Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. May 28, 2009. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed October 9, 2012.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
16. Jiang H, Tao W, Zhang M, Pan S, Kanwar JR and Sun X: Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice. Cancer Invest 28: 74-84, 2010.
17. Komuta K, Osaki T, Mori M, et al: A phase II study directed by a clinical pathway for carboplatin and weekly paclitaxel in previously untreated patients with unresectable non-small cell lung cancer. Chemotherapy 56: 39-45, 2010.
18. Sakakibara T, Inoue A, Sugawara S, et al: Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. Ann Oncol 21: 795-799, 2010.
19. Browder T, Butterfield CE, Kräling BM, et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886, 2000.
20. Drevs J, Fakler J, Eisele S, et al: Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 24: 1759-1763, 2004.
21. Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG and Sood AK: Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 67: 281-288, 2007.
22. Katsumata N, Yasuda M, Takahashi F, et al: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 371: 1331-1338, 2009.
23. Shaked Y, Emmenegger U, Man S, et al: Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106: 3058-3061, 2005.